Thursday, October 15, 2015 4:09:05 PM
The damages were assessed when Siga lost a fight with biodefense company PharmAthene Inc. (PIP) over smallpox drug Tecovirimat, which is now part of the Strategic National Stockpile, the country's biodefense arsenal of vaccines, antidotes and antitoxins.
Tecovirimat is believed to be useful in preventing or treating smallpox. It can be made in pill or capsule form, so it would be relatively easy to distribute in mass quantities in the event of a bio-attack.
Delaware's Court of Chancery in January told Siga to pay PharmAthene $194.6 million, a figure that includes $113 million in "expectation" damages for lost profits from Tecovirimat. Additionally, Siga's on the hook for interest of more than $30,000 per day, for each day the judgment goes unpaid.
Siga says the award was improperly calculated, and the lost profits were "speculative and too uncertain, contingent, and conjectural" to form the basis of a damages award for what it says was a failed licensing negotiation over an experimental drug of unknown potential.
"To put this award in perspective, it is greater than the market capitalizations of PharmAthene and Siga combined," Siga lawyer Stephen Lamb told the Delaware high court at Wednesday's hearing. Mr. Lamb is a former Court of Chancery judge.
"It is vital to Delaware's future as a significant commercial jurisdiction that this court reverse the judgment and rule that such speculative, indeed punitive, damages are not available," Mr. Lamb added.
PharmaAthene says there was no failed licensing negotiation and the damages were a proper remedy. According to PharmAthene, Siga experienced "seller's remorse" after the experimental drug started looking like a multibillion dollar hit.
PharmAthene urged the Delaware court to preserve the damages award or ask the lower court to consider awarding damages in the form of a share of cash flow generated from the drug. By PharmAthene's reckoning, it lost $400 million to $1 billion due to Siga's refusal to go through with the Tecovirimat deal.
Siga filed for chapter 11 protection in September 2014, short on cash and with the intention of continuing the court fight with PharmAthene.
In a recent bankruptcy-court filing, Siga said it is expecting a ruling from the Delaware Supreme Court by the end of the month or, at the latest, Jan. 5, 2016.
"Given the size of the Chancery Court's judgment and its potential impact on Siga's business, creditors, stockholders, and the entire plan process, the importance of pursuing the appeal to finality cannot be under-estimated," company lawyers said in the Sept. 10 bankruptcy court filing.
Recent SIGA News
- SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 09:00:00 PM
- SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- SIGA Names Larry Miller General Counsel • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- SIGA Declares Special Cash Dividend of $0.60 Per Share • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 08:54:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:04:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:28 PM
- SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:49:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:05:39 PM
- SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/26/2023 11:30:00 AM
- SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 10:05:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:05:20 PM
- SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 08:08:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 11:08:07 AM
- SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX® • GlobeNewswire Inc. • 07/27/2023 08:45:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM